
In this free webinar, learn how connected real-world, genomic and clinical data can support more accurate clinical trial feasibility and site selection. The featured speakers will discuss how protocol eligibility criteria can be matched to real patient populations, including biomarker-defined groups, using structured health data, genomic profiles and clinical notes. Attendees will also explore how combining these data sources can improve site prioritization and reduce enrollment risk earlier in study planning.
TORONTO, Oct. 20, 2026 /PRNewswire/ -- Clinical trial feasibility has long been constrained by the same fundamental problem: the data used to estimate patient availability rarely reflects the patients who will actually enroll. Site surveys capture what investigators think they have seen. Historical enrollment figures describe what happened in prior studies under different protocols. Neither answers the question that matters: do the right patients, with the right biology, exist at the right sites today?
This webinar introduces a new feasibility standard — one grounded in connected real-world evidence that spans structured clinical data, genomic and biomarker profiles and unstructured clinical notes. Together, these data layers allow sponsors and clinical operations teams to test protocol feasibility before sites are selected, not after activation has already committed resources to the wrong locations.
Samantha Eells, Solutions and Market Lead for Clinical Operations at TriNetX and Mark Hughes, Genomics Solution Engineer at TriNetX, will walk attendees through how deeper, more connected data transforms each stage of the feasibility process. Attendees will learn how to translate complex protocol eligibility criteria — including molecularly defined inclusion requirements — into queryable variables across real-world patient populations, how to identify sites where both the patient population and the operational evidence support successful enrollment and why combining structured EHR data with genomic profiles and clinical notes produces fundamentally more reliable feasibility estimates than any single data type alone.
For precision medicine studies, oncology trials and rare disease programs in particular, ICD and CPT codes alone cannot define the eligible population. A patient with the right diagnosis may lack the required biomarker. A site with high volume may have no genomic data coverage. This webinar addresses both gaps — and demonstrates how connecting these evidence layers earlier in study design reduces the risk of missed enrollment targets, delayed timelines and costly protocol amendments.
Attendees will leave with a practical framework for evidence-driven feasibility and a clearer picture of what it means to select sites based on confidence, not assumption.
Join experts from TriNetX, Samantha Eells, Solutions and Market Lead, Pharma Clinical Development & Clinical Operations; and Mark Hughes, Genomics Solution Engineer, for the live webinar on Wednesday, November 4, 2026, at 11am EST (5pm CET / EU-Central).
For more information, or to register for this event, visit Feasibility Without Guesswork: Unlocking Genomic and Real-World Data for Faster Study Execution.
ABOUT XTALKS
Xtalks – The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.
Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what's next.
To learn more about Xtalks, visit www.xtalks.com
For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/
Contact:
Soumya Shashikumar
Tel: +1 (416) 977-6555 x371
Email: [email protected]
SOURCE Xtalks
Share this article